Cellular senescence, telomere recombination and maintenance

Cytogenetic and Genome Research

Volumn 122, Issue 3-4, 2009, Pages 211-218

  Yang, Q ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN P53; PROTEIN POT1; REPETITIVE DNA; SINGLE STRANDED DNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERE BINDING PROTEIN; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL DIVISION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL PROTECTION; CELL STRESS; CELLULAR STRESS SIGNAL; CHROMOSOME SIZE; DNA BINDING MOTIF; DNA DAMAGE; GENE DUPLICATION; GENETIC RECOMBINATION; GENOMIC INSTABILITY; HUMAN; LIFESPAN; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TELOMERE;

CELL AGING; CELL DIVISION; DNA; DNA DAMAGE; DNA, NEOPLASM; FIBROBLASTS; HUMANS; NEOPLASMS; RECOMBINATION, GENETIC; TELOMERASE; TELOMERE; TELOMERE-BINDING PROTEINS;

EID: 59649109187     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167806     Document Type: Review

References (106)

1. Armanios M, Greider CW: Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol 70:205-208 (2005).
2. Bailey SM, Brenneman MA, Goodwin EH: Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res 32:3743-3751 (2004).
3. Baumann P, Cech TR: Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 292:1171-1175 (2001).
4. Baumann P, Podell E, Cech TR: Human Pot1 (protection of telomeres) protein: cytolocalization, gene structure, and alternative splicing. Mol Cell Biol 22:8079-8087 (2002).
5. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, et al: Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 22:4212-4222 (2003).
6. Blackburn EH: Switching and signaling at the telomere. Cell 106:661-673 (2001).
7. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, et al: Extension of life-span by introduction of telomerase into normal human cells. Science 279:349-352 (1998).
8. Bond JA, Haughton MF, Rowson JM, Smith PJ, Gire V, et al: Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol Cell Biol 19:3103-3114 (1999).
9. CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277:831-834 (1997).
10. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR: Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14:4240-4248 (1995).
11. Bryan TM, Englezou A, la-Pozza L, Dunham MA, Reddel RR: Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3:1271-1274 (1997).
12. Bunch JT, Bae NS, Leonardi J, Baumann P: Distinct requirements for Pot1 in limiting telomere length and maintaining chromosome stability. Mol Cell Biol 25:5567-5578 (2005).
13. Campisi J: Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120:513-522 (2005).
14. Celli GB, de Lange T: DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol 7:712-718 (2005).
15. Cesare AJ, Reddel RR: Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev 129:99-108 (2008).
16. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science 315:1850-1853 (2007).
17. Colgin LM, Baran K, Baumann P, Cech TR, Reddel RR: Human POT1 facilitates telomere elongation by telomerase. Curr Biol 13:942-946 (2003).
18. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and aging. Cell 130:223-233 (2007).
19. Compton SA, Choi JH, Cesare AJ, Ozgur S, Griffith JD: Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. Cancer Res 67:1513-1519 (2007).
20. Cong YS, Wen J, Bacchetti S: The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8:137-142 (1999).
21. d'Adda di Fagagna F: Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8:512-522 (2008).
22. de Lange T: Cell biology. Telomere capping - one strand fits all. Science 292:1075-1076 (2001).
23. de Lange T: Protection of mammalian telomeres. Oncogene 21:532-540 (2002).
24. de Lange T: T-loops and the origin of telomeres. Nat Rev Mol Cell Biol 5:323-329 (2004).
25. de Lange T: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19:2100-2110 (2005).
26. Denchi EL, de Lange T: Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448:1068-1071 (2007).
27. Dimitrova N, de Lange T: MDC1 accelerates non-homologous end-joining of dysfunctional telomeres. Genes Dev 20:3238-3243 (2006).
28. Dunham MA, Neumann AA, Fasching CL, Reddel RR: Telomere maintenance by recombination in human cells. Nat Genet 26:447-450 (2000).
29. Fasching CL, Neumann AA, Muntoni A, Yeager TR, Reddel RR: DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA. Cancer Res 67:7072-7077 (2007).
30. Feldser DM, Hackett JA, Greider CW: Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 3:623-627 (2003).
31. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, et al: The RNA component of human telomerase. Science 269:1236-1241 (1995).
32. Gottschling DE, Cech TR: Chromatin structure of the molecular ends of Oxytricha macronuclear DNA: phased nucleosomes and a telomeric complex. Cell 38:501-510 (1984).
33. Grandin N, Damon C, Charbonneau M: Cdc13 prevents telomere uncapping and Rad50-dependent homologous recombination. EMBO J 20:6127-6139 (2001).
34. Greider CW, Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43:405-413 (1985).
35. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, et al: Mammalian telomeres end in a large duplex loop. Cell 97:503-514 (1999).
36. Grobelny JV, Godwin AK, Broccoli D: ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci 24:4577-4585 (2000).
37. Hahn WC, Meyerson M: Telomerase activation, cellular immortalization and cancer. Ann Med 33:123-129 (2001).
38. Harley CB: Telomerase and cancer therapeutics. Nat Rev Cancer 8:167-179 (2008).
39. Hayflick L: The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 37:614-636 (1965).
40. Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 25:585-621 (1961).
41. He H, Multani AS, Cosme-Blanco W, Tahara H, Ma J, et al: POT1b protects telomeres from end-to-end chromosomal fusions and aberrant homologous recombination. EMBO J 25:5180-5190 (2006).
42. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, et al: X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 19:32-38 (1998).
43. Hockemeyer D, Sfeir AJ, Shay JW, Wright WE, de Lange T: POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J 24:2667-2678 (2005).
44. Hockemeyer D, Daniels JP, Takai H, de Lange T: Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 126:63-77 (2006).
45. Horikawa I, Barrett JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24:1167-1176 (2003).
46. Horvath MP, Schweiker VL, Bevilacqua JM, Ruggles JA, Schultz SC: Crystal structure of the Oxytricha nova telomere end binding protein complexed with single strand DNA. Cell 95:963-974 (1998).
47. INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res 58:3508-3512 (1998).
48. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, et al: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275:1649-1652 (1997).
49. Itahana K, Dimri G, Campisi J: Regulation of cellular senescence by p53. Eur J Biochem 268:2784-2791 (2001).
50. INK4a as a second effector of the telomere damage pathway. Cell Cycle 4:1364-1368 (2005).
51. Jiang WQ, Zhong ZH, Henson JD, Reddel RR: Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 26:4635-4647 (2007).
52. Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, et al: Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21:111-114 (1999).
53. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T: p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283:1321-1325 (1999).
54. Karlseder J, Smogorzewska A, de Lange T: Senescence induced by altered telomere state, not telomere loss. Science 295:2446-2449 (2002).
55. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015 (1994).
56. Konishi A, de Lange T: Cell cycle control of telomere protection and NHEJ revealed by a ts mutation in the DNA-binding domain of TRF2. Genes Dev 22:1221-1230 (2008).
57. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, et al: Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274:7936-7940 (1999).
58. Lei M, Podell ER, Baumann P, Cech TR: DNA self-recognition in the structure of Pot1 bound to telomeric single-stranded DNA. Nature 426:198-203 (2003).
59. Lei M, Podell ER, Cech TR: Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat Struct Mol Biol 11:1223-1229 (2004).
60. Lei M, Zaug AJ, Podell ER, Cech TR: Switching human telomerase on and off with hPOT1 protein in vitro. J Biol Chem 280:20449-20456 (2005).
61. Lingner J, Cech TR: Telomerase and chromosome end maintenance. Curr Opin Genet Dev 8:226-232 (1998).
62. Liu D, Safari A, O'Connor MS, Chan DW, Laegeler A, et al: PTOP interacts with POT1 and regulates its localization to telomeres. Nat Cell Biol 6:673-680 (2004).
63. Loayza D, de Lange T: POT1 as a terminal transducer of TRF1 telomere length control. Nature 424:1013-1018 (2003).
64. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR: Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 64:2324-2327 (2004).
65. Maser RS, DePinho RA: Connecting chromosomes, crisis, and cancer. Science 297:565-569 (2002).
66. Maser RS, DePinho RA: Telomeres and the DNA damage response: why the fox is guarding the henhouse. DNA Repair (Amst) 3:979-988 (2004).
67. Mitchell JR, Cheng J, Collins K: A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol Cell Biol 19:567-576 (1999).
68. Molenaar C, Wiesmeijer K, Verwoerd NP, Khazen S, Eils R, et al: Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J 22:6631-6641 (2003).
69. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, et al: Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21:115-118 (1999).
70. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-529 (1989).
71. Muntoni A, Reddel RR: The first molecular details of ALT in human tumor cells. Hum Mol Genet 14 Spec No. 2:R191-R196 (2005).
72. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959 (1997).
73. INK4 expression. Oncogene 13:1259-1268 (1996).
74. Nugent CI, Lundblad V: The telomerase reverse transcriptase: components and regulation. Genes Dev 12:1073-1085 (1998).
75. Olovnikov AM: A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 41:181-190 (1973).
76. Opresko PL, Mason PA, Podell ER, Lei M, Hickson ID, et al: POT1 stimulates RecQ helicases WRN and BLM to unwind telomeric DNA substrates. J Biol Chem 280:32069-32080 (2005).
77. Pennock E, Buckley K, Lundblad V: Cdc13 delivers separate complexes to the telomere for end protection and replication. Cell 104:387-396 (2001).
78. INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 15:4745-4753 (1995).
79. Shay JW, Woodring EW: Telomerase activity in human cancer. Curr Opin Oncol 8:66-71 (1996).
80. Shay JW, Wright WE: Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 5:577-584 (2006).
81. Sherr CJ, DePinho RA: Cellular senescence: mitotic clock or culture shock? Cell 102:407-410 (2000).
82. Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2:103-112 (2002).
83. Smogorzewska A, de Lange T: Different telomere damage signaling pathways in human and mouse cells. EMBO J 21:4338-4348 (2002).
84. Stansel RM, de Lange T, Griffith JD: T-loop assembly in vitro involves binding of TRF2 near the 3′ telomeric overhang. EMBO J 20:5532-5540 (2001).
85. Stewart SA, Ben Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA: Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 33:492-496 (2003).
86. Tahara H, Shin-Ya K, Seimiya H, Yamada H, Tsuruo T, Ide T: G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells. Oncogene 25:1955-1966 (2006).
87. Takai H, Smogorzewska A, de Lange T: DNA damage foci at dysfunctional telomeres. Curr Biol 13:1549-1556 (2003).
88. van Steensel B, Smogorzewska A, de Lange T: TRF2 protects human telomeres from end-to-end fusions. Cell 92:401-413 (1998).
89. Vaziri H, Benchimol S: Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8:279-282 (1998).
90. Vaziri H, Squire JA, Pandita TK, Bradley G, Kuba RM, et al: Analysis of genomic integrity and p53-dependent G1 checkpoint in telomerase-induced extended-life-span human fibroblasts. Mol Cell Biol 19:2373-2379 (1999).
91. Veldman T, Etheridge KT, Counter CM: Loss of hPot1 function leads to telomere instability and a cut-like phenotype. Curr Biol 14:2264-2270 (2004).
92. Wang F, Podell ER, Zaug AJ, Yang Y, Baciu P, et al: The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 445:506-510 (2007).
93. Wang J, Xie LY, Allan S, Beach D, Hannon GJ: Myc activates telomerase. Genes Dev 12:1769-1774 (1998).
94. Wang RC, Smogorzewska A, de Lange T: Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 119:355-368 (2004).
95. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, et al: Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 26:85-88 (2000).
96. Wu G, Lee WH, Chen PL: NBS1 and TRF1 colocalize at promyelocytic leukemia bodies during late S/G2 phases in immortalized telomerase-negative cells. Implication of NBS1 in alternative lengthening of telomeres. J Biol Chem 275:30618-30622 (2000).
97. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, et al: Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 126:49-62 (2006).
98. Xin H, Liu D, Wan M, Safari A, Kim H, et al: TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature 445:559-562 (2007).
99. Yang Q, Zheng YL, Harris CC: POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol 25:1070-1080 (2005).
100. Yang Q, Zhang R, Horikawa I, Fujita K, Afshar Y, et al: Functional diversity of human protection of telomeres 1 isoforms in telomere protection and cellular senescence. Cancer Res 67:11677-11686 (2007).
101. Ye JZ, Donigian JR, Van Overbeek M, Loayza D, Luo Y, et al: TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J Biol Chem 279:47264-47271 (2004a).
102. Ye JZ, Hockemeyer D, Krutchinsky AN, Loayza D, Hooper SM, et al: POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev 18:1649-1654 (2004b).
103. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR: Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 59:4175-4179 (1999).
104. Zaug AJ, Podell ER, Cech TR: Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc Natl Acad Sci USA 102:10864-10869 (2005).
105. Zhang H: Molecular signaling and genetic pathways of senescence: its role in tumorigenesis and aging. J Cell Physiol 210:567-574 (2007).
106. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T: ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell 12:1489-1498 (2003).